Boston Scientific Announces Agreement to Acquire Apama Medical

Acquisition to Strengthen Company’s Electrophysiology Portfolio and Expand into “Single-Shot” Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation

Oct 2, 2017

MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). The transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020 based on achievements of clinical and regulatory milestones.

Press Release